{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:09:53Z","timestamp":1780355393750,"version":"3.54.1"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The contraceptive pill is an effective and very safe method to control pregnancies. It was developed 60 years ago, and despite that the composition has been the same since it was first developed (estrogen and progestogen), over the years the concentration of ethinyl estradiol has been reduced to improve tolerability. Nevertheless, progestogens are the basic active agent of hormonal contraception. The mechanism of progestogens is a multimodal one and basically three modes of contraceptive action can be distinguished: (a) A strong antigonadotrophic action leading to the inhibition of ovulation. The necessary dosage of ovulation inhibition per day is a fixed dosage that is intrinsic to each progestogen and independent of the dosage of estrogen used or the partial activities of the progestogen or the mode of application. (b) Thickening of the cervical mucus to inhibit sperm penetration and (c) desynchronization of the endometrial changes necessary for implantation. The on the market available progestogens used for contraception are either used in combined hormonal contraceptives (in tablets, patches or vaginal rings) or as progestogen only contraceptives. Progestogen only contraceptives are available as daily oral preparations, monthly injections, implants (2\u20133 years) and intrauterine systems (IUS). Even the long-acting progestogens are highly effective in typical use and have a very low risk profile. According to their introduction into the market, progestogens in combined hormonal contraceptives, have been described as 1st, 2nd, 3rd and 4th generation progestogens. The different structures of progestogens are derivatives from testosterone, progesterone and spironolactone. These differences in the molecular structure determine pharmacodynamic and pharmacokinetic differential effects which contribute to the tolerability and additional beneficial or therapeutic effects whether used in combined oral contraceptive (COC) or as progestogen only drugs. These differences enhance the individual options for different patient profiles. The new development of polymers for vaginal rings allowed on the one hand, the improvement of the estrogen\/progestogen combination in these rings especially regarding the comfort of use for women (e.g. avoiding the use of cold chains or packages with up to 6-month rings) and on the other hand, the development of progestogen only formulations. Another future development will be the introduction of new progestogen only pills that will provide effective contraceptive protection with more favorable bleeding patterns and a maintenance of ovulation inhibition after scheduled 24-h delays in pill intake than the existing progestogen only pill (POP) with desogestrel (DES).<\/jats:p>","DOI":"10.1515\/hmbci-2018-0030","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T05:07:25Z","timestamp":1540616845000},"source":"Crossref","is-referenced-by-count":14,"title":["Clinical relevance in present day hormonal contraception"],"prefix":"10.1515","volume":"37","author":[{"given":"Pedro-Antonio","family":"Regidor","sequence":"first","affiliation":[{"name":"Medical Director, Europe and Germany , Adalperostra\u00dfe 84, 85737 Ismaning , Germany , Phone: +49 89 4520529 ext. 19, Mobile: +491738938132, Fax: +49 89 4520529 ext. 819"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"key":"2025121207110105214_j_hmbci-2018-0030_ref_001_w2aab3b7b6b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171\u201380.","DOI":"10.1016\/j.maturitas.2008.11.013"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_002_w2aab3b7b6b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11:41\u20137.","DOI":"10.5812\/ijem.4158"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_003_w2aab3b7b6b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010;82:396\u2013403.","DOI":"10.1016\/j.contraception.2010.05.005"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_004_w2aab3b7b6b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008;77:1\u20135.","DOI":"10.1016\/j.contraception.2007.09.001"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_005_w2aab3b7b6b1b6b1ab2b1b5Aa","unstructured":"Brown SS, Eisenberg L. editors. The best intentions: unintended pregnancy and the well-being of children and families. Washington, DC: National Academy Press; 1995."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_006_w2aab3b7b6b1b6b1ab2b1b6Aa","unstructured":"PRAC referral assessment report. Procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data. Combined hormonal contraceptives containing medicinal products INN: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate. Procedure number: EMEA\/H\/A-31\/1356. 15 October 2013."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_007_w2aab3b7b6b1b6b1ab2b1b7Aa","unstructured":"Opinion of the Committee for Medicinal Products for Human Use pursuant to Article 31 of Directive 2001\/83\/ EC for dienogest\/ethinylestradiol containing medicinal products indicated in acne. EMA\/CHMP\/562861\/2016. Committee for Medicinal Products for Human Use. EMEA\/ H\/A-31\/1435. January 2017."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_008_w2aab3b7b6b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Djerassi C. Steroid research at Syntex: \u201cthe pill\u201d and cortisone. Steroids. 1992;57:631\u201341.","DOI":"10.1016\/0039-128X(92)90016-3"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_009_w2aab3b7b6b1b6b1ab2b1b9Aa","unstructured":"Kuhl H. Pharmacology of progestogens. J Reproduct Endocrinol. 2011;8:157\u201376."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_010_w2aab3b7b6b1b6b1ab2b1c10Aa","unstructured":"Wiechert R, Bittler D, Krebs U, Casals-Stenzel J, Losert W, Deutsches Patent Nr. 2652761 (Priorit\u00e4t: 1976)."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_011_w2aab3b7b6b1b6b1ab2b1c11Aa","unstructured":"Wiechart R. Analogue based drug discovery. In: Fisher J, Robin Ganellin C, editors. IUPAC. Weinheim, Germany: Wiley VCH; 2006. p. 395\u2013400."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_012_w2aab3b7b6b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"De Lignier\u00e8s B, Dennerstein L, backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995;21:251\u20137.","DOI":"10.1016\/0378-5122(94)00882-8"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_013_w2aab3b7b6b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocrinol Rev. 1997;52:502\u201319.","DOI":"10.1210\/edrv.18.4.0308"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_014_w2aab3b7b6b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8:83334\u201342.","DOI":"10.18632\/oncotarget.19833"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_015_w2aab3b7b6b1b6b1ab2b1c15Aa","unstructured":"Rabe T, Ahrendt HJ, Merkle E, Peters K, Albring C, Bitzer J, et al. Hormonimplantate zur Kontrazeption bei der Frau. J Reproduktionsmed Endokrinol. 2013;10:168\u201380."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_016_w2aab3b7b6b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fracture. Contraception. 2006;73:571\u20136.","DOI":"10.1016\/j.contraception.2006.01.006"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_017_w2aab3b7b6b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010;95:4909\u201316.","DOI":"10.1210\/jc.2010-0032"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_018_w2aab3b7b6b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012:86;606\u201321.","DOI":"10.1016\/j.contraception.2012.04.009"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_019_w2aab3b7b6b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Isley MM, Kaunitz AM. Update on hormonal contraception and bone density. Rev Endocr Metab Disord. 2011;12:93\u2013106.","DOI":"10.1007\/s11154-011-9180-6"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_020_w2aab3b7b6b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Thijssen JHH. Long-term effects of progestins on bone quality and fractures. Gynecol Endocrinol. 2007;23:45\u201352.","DOI":"10.1080\/09513590701584931"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_021_w2aab3b7b6b1b6b1ab2b1c21Aa","unstructured":"R\u00f6mer T. Aktuelles: Intrauterine hormonelle Kontrazeption. J Gyn\u00e4kol Endokrinol. 2012;4:16\u201322."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_022_w2aab3b7b6b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Melvin L, Scott J, Craik J. Jaydess\u00ae levonorgestrel intrauterine system. J Fam Plann Reprod Health Care. 2014;40:165\u20139.","DOI":"10.1136\/jfprhc-2014-100980"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_023_w2aab3b7b6b1b6b1ab2b1c23Aa","unstructured":"WHO. Medical eligibility criteria for contraceptive use. 5th ed. WHO; 2015, p. 161. ISBN 978 92 4 1549 15 8."},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_024_w2aab3b7b6b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Rice CF, Killick SR, Dieben T, Bennink HC. A comparison of the inhibition of ovulation achieved by desogestrel 75 mg and levonorgestrel 30 mg daily. Hum Reprod. 1999;14:982\u20135.","DOI":"10.1093\/humrep\/14.4.982"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_025_w2aab3b7b6b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Sarfati J, de Vernejoul MC. Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine. 2009;76:134\u20138.","DOI":"10.1016\/j.jbspin.2008.09.014"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_026_w2aab3b7b6b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Rice C, Killick S, Hickling D, Bennink HC. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod. 1996;11:737\u201340.","DOI":"10.1093\/oxfordjournals.humrep.a019245"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_027_w2aab3b7b6b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Algorta J, Diaz M, de Benito R, Lefebvre M, Sicard E, Furtado M, et al. Pharmacokinetic bioequivalence, safety and acceptability of Ornibel\u00ae, a new polymer composition contraceptive vaginal ring (etonogestrel\/ethinylestradiol 11.00\/3.474\u2009mg) compared with Nuvaring\u00ae (etonogestrel\/ethinylestradiol 11.7\/2.7\u2009mg). Eur J Contracept Reprod Health Care. 2017;22:429\u201338.","DOI":"10.1080\/13625187.2017.1413179"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_028_w2aab3b7b6b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92:439\u201344.","DOI":"10.1016\/j.contraception.2015.07.014"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_029_w2aab3b7b6b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016;93:303\u20139.","DOI":"10.1016\/j.contraception.2015.12.007"},{"key":"2025121207110105214_j_hmbci-2018-0030_ref_030_w2aab3b7b6b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4\u2009mg formulation in a 24+4 cycle with desogestrel 75\u2009\u03bcg per day. Gynecol Endocrinol. 2016;32:749\u201351.","DOI":"10.3109\/09513590.2016.1161743"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2019.37.issue-1\/hmbci-2018-0030\/hmbci-2018-0030.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2018-0030\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2018-0030\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:55:15Z","timestamp":1765526115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2018-0030\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,8,18]]},"published-print":{"date-parts":[[2019,1,28]]}},"alternative-id":["10.1515\/hmbci-2018-0030"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2018-0030","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,26]]},"article-number":"20180030"}}